APP13007, 0.05%

DRUG3 trials

Sponsors

Formosa Pharmaceuticals, Inc.

Conditions

Ocular Inflammation and PainOcular Inflammation and Pain After Cataract Surgery

Phase 2

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

CompletedNCT04089735

Formosa Pharmaceuticals, Inc.Ocular Inflammation and Pain After Cataract Surgery

Start: 2019-08-13End: 2020-04-07Updated: 2023-06-27

Phase 3

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

CompletedNCT04739709

Formosa Pharmaceuticals, Inc.Ocular Inflammation and Pain

Start: 2021-01-11End: 2022-03-17Updated: 2023-07-20

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

CompletedNCT04810962

Formosa Pharmaceuticals, Inc.Ocular Inflammation and Pain After Cataract Surgery

Start: 2021-03-16End: 2022-07-06Updated: 2023-07-25